You're contacting media contact of this press release

Title: MEnera The Innovative OTC Biologic Revolutionizing Womens Reproductive Health

Tampa, Florida, United States, 19th Jun 2025 - Women seeking scientifically validated solutions for hormonal balance and fertility enhancement now have a promising option on the horizon. Medicinal Technologies, a pioneering biopharmaceutical company based in the U.S., has announced its plans to release MEnera in late 2025. This innovative over-the-counter biologic is designed to tackle issues like menstrual irregularities, menopausal symptoms, PCOS, and infertility.MEnera represents the culmination of years of research into small cell biologics, drawing inspiration from the groundbreaking Tejeda Equation, which identified key molecular contributors to conditions such as endometriosis. According to lead medical scientist Dr. Sheryene Tejeda, MEnera works by targeting the root causes of endocrine dysfunction, offering a pathway to restore hormonal balance without relying on synthetic compounds.Dr. Tejeda emphasized that MEnera embodies a turning point in personal health, delivering genuine biological improvements supported by clinical science rather than superficial marketing claims. Women who struggle with hormonal imbalances, fatigue, low libido, poor egg quality, menopausal symptoms, irregular cycles, or fertility challenges can look forward to MEnera’s targeted solutions. The product is being made available at an accessible price point, backed by Medicinal Technologies’ commitment to scientific integrity and consumer safety. It will be distributed through local pharmacies across the U.S.As an FDA-registered and closely supervised OTC drug targeting both endocrine and cellular levels, MEnera is the suitable choice for women coping with PCOS or contemplating conception and IVF procedures, grounded in comprehensive research rather than fleeting trends. Beyond its im...

This press release is issued by King Newswire